Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Yu EY, et al. Among authors: posadas em. Urology. 2011 May;77(5):1166-71. doi: 10.1016/j.urology.2011.01.006. Urology. 2011. PMID: 21539969 Free PMC article. Clinical Trial.
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. Antonarakis ES, et al. Among authors: posadas em. Cancer Chemother Pharmacol. 2013 Apr;71(4):883-92. doi: 10.1007/s00280-013-2079-z. Epub 2013 Jan 13. Cancer Chemother Pharmacol. 2013. PMID: 23314737 Free PMC article. Clinical Trial.
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI. Autio KA, et al. Among authors: posadas em. JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168. JAMA Oncol. 2018. PMID: 29978216 Free PMC article. Clinical Trial.
Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.
Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N. Alyamani M, et al. Among authors: posadas em. Ann Oncol. 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11. Ann Oncol. 2020. PMID: 32057540 Free PMC article.
Disparities in Cancer Care and the Asian American Population.
Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY. Lee RJ, et al. Among authors: posadas em. Oncologist. 2021 Jun;26(6):453-460. doi: 10.1002/onco.13748. Epub 2021 Mar 20. Oncologist. 2021. PMID: 33683795 Free PMC article. Review.
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL 3rd, Shen J, Gururajan M, Sievert M, Stadler WM. Posadas EM, et al. Prostate. 2016 Feb 15;76(3):286-93. doi: 10.1002/pros.23119. Epub 2015 Oct 23. Prostate. 2016. PMID: 26493492 Free PMC article. Clinical Trial.
135 results